- Home
- Advocacy
- Latest News and Practice Data
- CAP Advocacy Expands Thyroid Cancer Molecular Testing Coverage
On June 13, the Palmetto MolDX program and its participating Medicare Administrative Contractors (MACs), Cigna Government Services, Noridian and Wisconsin Physicians Service, posted final versions of a local coverage determination (LCD) regarding molecular testing for risk stratification of thyroid nodules. Palmetto and the contractors adopted recommendations from the CAP before finalizing the new coverage policy.
In an October 2023 comment letter to the MACs, the CAP opposed the LCD proposal that would have limited coverage only to patients who had not been tested with the same or similar assay for the same clinical indication. The CAP recommended that coverage include patients with multiple concurrent indeterminate nodules or who develop new nodules over time. The MACs agreed and the final coverage policy includes the CAP’s recommendations.
The coverage policy takes effect July 28, 2024, and applies to 23 states and several US territories.